Specifically, we analyzed performance in an extensive dual-task training setting (involving training sessions across several days) combining an auditory-vocal task and a visual-manual task. The results indicated that, throughout practice, nearly all relevant comparisons of performance between complete switch trials (e.g., between the two single tasks) and partial repetition trials (e.g., from dual to single task) revealed partial repetition benefits, that is, for both the auditory-vocal and the visual-manual task, and for both single- and dual-task performance analyses. Therefore, dual-action requirements in the present dual-task setting are mentally represented in a compositional, Structuralist fashion, probably due to low between-task dimensional overlap.The Participatory One-Health Disease Detection project (PODD) (www.cmonehealth.org) developed a health-based surveillance system with the local government of Chiang Mai community ownership that has been created a mobile application on smartphone for reporting an abnormal event, especially animal health. Previously, the PODD project has obtained a significant number of pig abnormal events. Therefore, there are likely to be some diseases that are currently circulating among backyard pigs. A cross-sectional serological study was undertaken to determine the risk factors for virus infection and prevalence of antibodies against the classical swine fever virus (CSFV), porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2) and influenza A virus (IAV) among backyard pigs in Chiang Mai, Thailand. Antibodies against the CSFV, PRRSV and PCV2 in backyard pigs were shown in swine level to be 14 % (95 % CI 9-20), 14 % (95 % CI 10-19), and 15 % (95 % CI 8-23), respectively. For the houstrict regulation of pig imports as a free source of the viruses along with effective animal quarantine, policies, and appropriate vaccination programs.
  Squamous cell carcinoma of the tongue (SCCT) is preferably treated by surgery. Free resection margins (≥5 mm) provide local control and disease-free survival. However, close (1-5mm) and positive margins (<1 mm) are frequently encountered. We present our first experience of in-vivo ultrasound (US) guided SCCT resections followed by ex-vivo US control on the resection specimen to obtain free margins. We compare the results with those from a hisorical cohort of 91 conventionally treated SCCT patients.
 
  Ten patients with SCCT were included in a consecutive US-cohort. We aimed for a 5-10mm margin during surgery, while we visualized the resection plane on US. Ex-vivo US measurements on the resection specimen determined whether there was any need for an immediate re-resection. US measurements were then compared with histopathology. Histopathological margins were compared with a consecutive cohort of 91 patients who had undergone conventional surgery for a SCCT.
 
  In the US cohort, 70% of the margins were free. In the conventional cohort, this figure was 17% (P=0.005). US predicted minimal histopathological margin distance with a mean±SD error of 1.9±1.8mm. The mean±SD of the histopathological overall submucosal/deep margin distance was 7.9±2.1mm in the US cohort and 7.0±2.2mm in the conventional cohort (P=0.188). Ex-vivo examination through use of US indicated an immediate re-resection, which prevented local adjuvant treatment.
 
  Use of US-guided SCCT resection is feasible and improves margin control.
 Use of US-guided SCCT resection is feasible and improves margin control.Abnormally alternative splicing events are common hallmark of diverse types of cancers. Splicing variants with aberrant functions play an important role in cancer development. Most importantly, a growing body of evidence has supported that alternative splicing might play a significant role in the therapeutic resistance of tumors. Targeted therapy and immunotherapy are the future directions of tumor therapy; however, the loss of antigen targets on the tumor cells surface and alterations in drug efficacy have resulted in the failure of targeted therapy and immunotherapy. Interestingly, abnormal alternative splicing, as a strategy to regulate gene expression, is reportedly involved in the reprogramming of cell signaling pathways and epitopes on the tumor cell surface by changing splicing patterns of genes, thus rendering tumors resisted to targeted therapy and immunotherapy. Accordingly, increased knowledge regarding abnormal alternative splicing in tumors may help predict therapeutic resistance during targeted therapy and immunotherapy and lead to novel therapeutic approaches in cancer. Herein, we provide a brief synopsis of abnormal alternative splicing events in cancer progression and therapeutic resistance.
  The aim of the present study was to evaluate the safety and efficacy of the add-on treatment of stiripentol (STP) in adult patients with severely pharmacoresistant focal or multifocal epilepsy.
 
  Data on adult patients treated with STP from March 2007 to July 2020 and with at least one clinical follow-up (FU) were retrospectively reviewed.  https://www.selleckchem.com/products/phtpp.html  Data on tolerability, efficacy and concomitant medication were evaluated at baseline, 6 months (5.5 ± 1.6 months (mean ± SD)) and 12 months (13.1 ± 3.9 months (mean ± SD)).
 
  Data of 22 patients (54.5% male, mean age 34.4 ± 17.79 years (mean ± SD), including mean duration of epilepsy 17.6 ± 25.5 years (mean ± SD), median seizure frequency 30 ± 20 (median ± MAD) per month, and 63.6% being severely intellectually disabled, with 3 to 18 previous anti-seizure-drugs (ASD), were collected. After 6 months, 72.7% of the patients were still taking STP, and 31% of the patients were responders, including 13% who were seizure-free. The 12-month retention rate was 54.4 %, the response rate was 36.4% and 13.6% of patients were seizure-free at the 12-month FU. Reasons for discontinuation were increased seizure frequency, hyperammonaemia and encephalopathy.
 
  STP seems to be a useful option in the treatment of patients with severely pharmacoresistant epilepsy. Prospective trials are necessary to examine the efficacy of STP in adult patients with pharmacoresistant focal epilepsy.
 STP seems to be a useful option in the treatment of patients with severely pharmacoresistant epilepsy. Prospective trials are necessary to examine the efficacy of STP in adult patients with pharmacoresistant focal epilepsy.